Jessica L. Taylor, MD
Assistant Professor, Medicine
Biography
Jessica L. Taylor, MD is an Assistant Professor of Medicine in General Internal Medicine at the Chobanian and Avedisian School of Medicine and Boston Medical Center and a board-certified Addiction Specialist. She attended Mount Sinai School of Medicine and completed internal medicine residency training at Beth Israel Deaconess Medical Center and Harvard Medical School, where she also served as a Chief Resident. Dr. Taylor’s clinical work focuses on the care of patients with substance use disorders, HIV, and viral hepatitis.
Her research interests include HIV prevention among people who inject drugs, HIV pre-exposure prophylaxis (PrEP) implementation, low-barrier substance use disorder treatment models, and overdose prevention. She is Co-Director of the Care Continuum Core for the Massachusetts site of the NIDA-funded Healing Communities Study, which aims to reduce fatal opioid overdose by 40%.
Dr. Taylor is the Medical Director of Faster Paths to Treatment, Boston Medical Center’s innovative, low-barrier substance use disorder bridge clinic and the Medical Director of the Transitional Care Clinic, a bridge clinic co-located with a low-threshold, transitional housing program for people experiencing homelessness. She directs HIV Prevention Programs at BMC. Her educational roles include directing the HIV Pathway for internal medicine residents and serving as core faculty in BUSM’s Addiction Medicine fellowship program.
Other Positions
- Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University Chobanian & Avedisian School of Medicine
Education
- Mount Sinai School of Medicine, MD
- Duke University, BS
Publications
- Published on 10/14/2024
De La Hoz A, Gadi N, Lopez CG, Barrera-Godinez A, Miller NS, Bourque DL, Brem C, Ozluk E, Seth G, Kimball S, Taylor JL. Immune Reconstitution Inflammatory Syndrome in a Patient With Cutaneous Leishmaniasis and HIV: A Diagnostic Challenge for Clinicians Caring for a Migrant Population in the United States. Open Forum Infect Dis. 2024 Oct; 11(10):ofae587. PMID: 39474451.
Read at: PubMed - Published on 6/26/2024
Laks J, Kim TW, Christine PJ, Evans J, Farrell NM, Kehoe J, Younkin M, Taylor JL. Treating Benzodiazepine Withdrawal in a Bridge Clinic. J Addict Med. 2024 Jun 26. PMID: 38922639.
Read at: PubMed - Published on 6/11/2024
Taylor C, Loukas V, Muwonge J, Taylor JL, Boyle J. Early Surgical Excision of Necrotic Tissue Following Unintentional Dermal Injection of Extended-Release Buprenorphine. J Addict Med. 2024 Sep-Oct 01; 18(5):605-607. PMID: 38869178.
Read at: PubMed - Published on 6/3/2024
Harris MT, Weinberger E, O'Brien C, Althoff M, Paltrow-Krulwich S, Taylor JL, Judge A, Samet JH, Walley AY, Gunn CM. PrEP facilitators and barriers in substance use bridge clinics for women who engage in sex work and who use drugs. Addict Sci Clin Pract. 2024 Jun 03; 19(1):47. PMID: 38831359.
Read at: PubMed - Published on 5/12/2024
Taylor JL, Gott J, Weisenthal K, Colicchio P, Dyer S, Komaromy MS. Post-Overdose Extended-Release Buprenorphine Initiation Facilitated by a Partnership Between Emergency Medical Services and an Outpatient Substance Use Disorder Observation Unit. Subst Use Addctn J. 2024 Oct; 45(4):771-776. PMID: 38736211.
Read at: PubMed - Published on 2/16/2024
Lewis NM, Smeltzer RP, Baker TJ, Sahovey AC, Baez J, Hensel E, Poole B, Stewart C, Cogan AG, Bullard M, Taylor JL. Feasibility of paying people who use drugs cash to distribute naloxone within their networks. Harm Reduct J. 2024 Feb 16; 21(1):42. PMID: 38365734.
Read at: PubMed - Published on 2/8/2024
Shahlapour M, Singh S, Christine PJ, Laks J, Evans J, Farrell NM, Khan GK, Taylor JL, Rozansky H. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic. J Addict Med. 2024 May-Jun 01; 18(3):345-347. PMID: 38329815.
Read at: PubMed - Published on 2/1/2024
Stewart J, Ruiz-Mercado G, Sperring H, Pierre CM, Assoumou SA, Taylor JL. Addressing Unmet PrEP Needs in Women: Impact of a Laboratory-Driven Protocol at an Urban, Essential Hospital. Open Forum Infect Dis. 2024 Mar; 11(3):ofae056. PMID: 38464490.
Read at: PubMed - Published on 1/16/2024
Taylor JL, Lasser KE. Intranasal Naloxone for Opioid Overdose. JAMA. 2024 Jan 16; 331(3):250-251. PMID: 38127361.
Read at: PubMed - Published on 12/19/2023
Chatterjee A, Baker T, Rudorf M, Walt G, Stotz C, Martin A, Kinnard EN, McAlearney AS, Bosak J, Medley B, Pinkhover A, Taylor JL, Samet JH, Lunze K. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions. J Subst Use Addict Treat. 2024 Apr; 159:209272. PMID: 38128649.
Read at: PubMed
View 34 more publications: View full profile at BUMC